Here is the structural logic of the modern pharmaceutical industry, stated plainly:
A cured patient is a lost customer. A chronically managed patient is a lifetime revenue stream.
This is not cynicism. It is not conspiracy. It is the straightforward, mathematically inevitable outcome of organizing health care as a for-profit enterprise within a system that rewards shareholder returns above all other values. When the primary obligation of a corporation is to maximize quarterly earnings, and when a sick population generates more revenue than a healthy one, the system will — must — orient toward the perpetuation of illness.
And it has.
The global pharmaceutical industry generates over $1.5 trillion in annual revenue. It is among the most profitable industries in human history, consistently outperforming oil, banking, and technology in profit margins. The top pharmaceutical companies maintain net profit margins of 15-25% — not on luxury goods, but on medicines that people need to survive.
This industry spends more on marketing than on research. In the United States alone, pharmaceutical companies spend approximately $30 billion per year on marketing to physicians and $6 billion on direct-to-consumer advertising. The United States and New Zealand are the only two countries on Earth that permit direct-to-consumer pharmaceutical advertising on television. Every evening, Americans are told by smiling actors to "ask your doctor" about drugs for conditions many of them did not know they had until they saw the commercial.
The industry spends more on lobbying than any other sector. Over $370 million annually in the US alone — more than defense, more than oil, more than technology. It employs roughly two lobbyists for every member of Congress. These lobbyists write the legislation that regulates their own industry, draft the rules that govern drug approval, and shape the policies that determine which treatments insurance will cover and which it will not.
Consider insulin.
Insulin was discovered in 1921 by Frederick Banting and Charles Best. Banting sold the patent to the University of Toronto for one dollar, believing that a medicine essential to human survival should never be a source of private profit. "Insulin does not belong to me," he said. "It belongs to the world."
A century later, the three companies that control the global insulin market — Eli Lilly, Novo Nordisk, and Sanofi — charge between $275 and $350 per vial in the United States for a product that costs approximately $2 to $6 to produce. The price of insulin tripled between 2002 and 2013 alone. One in four diabetic Americans has rationed insulin due to cost. People have died — not from diabetes, but from the inability to afford the medication that manages it.
This is not a market price. It is a monopoly rent extracted from captive customers whose alternative is death.
Consider EpiPens. The epinephrine auto-injector — a device that costs a few dollars to manufacture — was priced at $609 for a two-pack by Mylan Pharmaceuticals after the company acquired the product and raised the price by over 400%. Epinephrine itself costs less than a dollar. The device is a simple spring-loaded syringe. The price is not a reflection of value delivered. It is a reflection of power exercised.
Regulatory capture is the process by which regulatory agencies come to serve the interests of the industries they are supposed to oversee. In the pharmaceutical sector, this capture is essentially complete.
The FDA — the United States Food and Drug Administration — receives approximately 65% of its drug review budget from pharmaceutical company "user fees" paid under the Prescription Drug User Fee Act. The agency tasked with determining whether drugs are safe and effective is majority-funded by the companies seeking approval for those drugs.
The result is predictable. Approval times have shortened. Safety review periods have compressed. Post-market surveillance — the monitoring of drugs after they reach the public — is chronically underfunded and understaffed. Drugs are approved on the basis of short-term clinical trials funded and designed by their manufacturers, with negative results routinely suppressed or buried.
The revolving door between the FDA and the pharmaceutical industry spins without interruption. Former FDA commissioners, division directors, and senior reviewers routinely take positions on the boards and in the executive suites of the companies they previously regulated. Former pharmaceutical executives take positions at the FDA. The regulator and the regulated are not adversaries — they are colleagues, moving between offices in the same building of shared interests.
The opioid epidemic stands as the most devastating recent demonstration of what this system produces when operating exactly as designed.
In the mid-1990s, Purdue Pharma introduced OxyContin — a time-release formulation of oxycodone — and marketed it aggressively to physicians as a safe, non-addictive treatment for chronic pain. Sales representatives were trained to minimize addiction risks. Medical journals published favorable studies. The FDA approved the drug with a label suggesting it was less addictive than other opioids — a claim based on a single, uncontrolled study.
OxyContin was not non-addictive. It was profoundly addictive. Purdue Pharma's own internal documents — later revealed through litigation — showed that the company knew this. They knew patients were becoming dependent. They knew pills were being crushed and snorted to bypass the time-release mechanism. They knew people were dying. They continued marketing. They expanded sales territories. They increased quotas.
The result: over 500,000 Americans dead from opioid overdoses between 1999 and 2020. Millions more addicted, their lives shattered. Entire communities hollowed out. Children orphaned. Emergency rooms overwhelmed. Morgues overflowing.
Purdue Pharma was eventually fined and entered bankruptcy. The Sackler family, which owned the company and extracted over $10 billion in profits during the epidemic, negotiated legal protections from future lawsuits. No executive served prison time.
The system worked exactly as it was designed to work. Profit was maximized. Liability was managed. The dead were externalities.
Meanwhile, the approaches that address the root causes of illness are systematically marginalized.
Nutrition. Exercise. Stress reduction. Community. Purpose. Connection to the living world. Sleep. Clean air and water. Meaningful work. Spiritual practice. These are not alternative medicine. They are the foundations of health that every human civilization recognized for millennia before the pharmaceutical era.
They share one critical characteristic: they cannot be patented.
Medical schools in the United States dedicate an average of fewer than 25 hours over four years to nutrition education — in a nation where the leading causes of death (heart disease, cancer, diabetes, stroke) are overwhelmingly linked to diet and lifestyle. Physicians are trained to diagnose disease and prescribe pharmaceuticals. They are not trained to cultivate health.
Insurance reimbursement structures reinforce this orientation. A fifteen-minute office visit resulting in a prescription is reimbursed. An hour-long conversation about diet, stress, relationships, and purpose is not — or is reimbursed at a fraction of the rate. The financial architecture of health care systematically rewards intervention over prevention, treatment over healing, management over cure.
The mental health crisis exposes the deepest failure of this paradigm.
Anxiety, depression, and suicide have reached epidemic proportions across the developed world. Among young people, the numbers are catastrophic — teen depression has increased by over 60% since 2010, and suicide is now a leading cause of death for ages 10-24 in the United States.
The primary medical response is pharmaceutical: SSRIs, SNRIs, benzodiazepines, antipsychotics. These medications can alleviate symptoms for some patients, and that alleviation can be genuinely life-saving. This must be acknowledged.
But the epidemic itself demands a different question: Why are so many people suffering?
The answer is not a collective neurotransmitter deficiency. It is not a mass genetic malfunction. The answer is that human beings are living in conditions fundamentally incompatible with human flourishing — isolated from community, disconnected from purpose, immersed in toxic environments, saturated with information designed to manipulate rather than inform, severed from the natural world, burdened by economic precarity, and deprived of the spiritual and relational foundations that give life meaning.
These are not medical problems. They are civilizational problems. And no pharmaceutical can solve them.
A system designed to profit from illness will never produce health. It will produce patients. It will produce dependency. It will produce a population chronically managed, perpetually medicated, and structurally prevented from accessing the root conditions of well-being.
This is not a failure of the system. It is the system functioning precisely as designed.
Forward to 5.4 The Collapse of the Web of Life Back to 5.2 The Poisoning of Air, Water, and Soil Back to table of contents Most People Have No Idea What Is Coming